Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan

Anish Patel, COO of Enliven Therapeutics, sold 4,875 shares of common stock on March 6, 2024, at a weighted average price of $15.6387, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, sold 4,875 shares of the company's common stock on March 6, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 29, 2023.
• The shares were sold at prices ranging from $15.19 to $15.97, with a weighted average sale price of $15.6387.
• Following the transaction, Patel directly owns 7,472 shares and indirectly owns 394,027 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives who often use 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates